News | Contrast Media | August 15, 2017

ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents

New clinical and research guidelines urge caution when using gadolinium-based contrast, which evidence suggests can accumulate in the brain

ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents

August 15, 2017 — The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the use of contrast agents during MRI scans. Emerging research suggests gadolinium-based contrast agents, injected in a patient's veins to brighten tissues in MRI images, accumulate in the brain. More than 300 million doses of such drugs have been administered since their introduction in 1987.

"Small amounts of gadolinium deposit in certain parts of the brain in people who undergo repeated gadolinium-based contrast agent enhanced exams," said Vikas Gulani, M.D., Ph.D., associate professor of radiology, urology and biomedical engineering at Case Western Reserve University School of Medicine, member of the Case Comprehensive Cancer Center, and director of magnetic resonance imaging at University Hospitals Cleveland Medical Center. "The ISMRM response is a review of the literature and a series of recommendations on what the community ought to do in response to this phenomenon." Gulani helped craft the new recommendations and served as first author for the review, featured on the cover of The Lancet Neurology.

In the review, Gulani and other experts suggest if gadolinium is not needed for a particular exam, it should not be administered. A risk-benefit analysis should happen for all exams. "Nearly everyone needs an MRI scan at some point, often contrast enhanced," Gulani said. "The idea that some gadolinium could be depositing in the brain is disconcerting to patients. In that situation, putting the risk and benefits into context is important." If gadolinium is needed, it should be administered and the choice of agent is dependent on a large number of factors, only one of which is the deposition phenomenon.

Defining harm is an important consideration. Gadolinium-based contrast agents have a proven track record for accurate diagnosis and treatment monitoring of a large number of diseases including cancer, neurological pathology, heart disease, liver disease, and many other important conditions afflicting adults and children. They are associated with few side effects, the most serious of which are extremely infrequent and affect already sick patients with severe kidney failure. The new review does not suggest sweeping changes in the use of MRI contrast agents, as at present, there is no evidence linking the brain deposits to health risks. However, it provides clarity about the previously unknown phenomenon of gadolinium deposition in the brain and provides guidance for future research.

For more information: www.thelancet.com/neurology

Related Content

Toshiba Showcases MRI Workflow Enhancements at RSNA 2017
News | Magnetic Resonance Imaging (MRI) | September 21, 2017
September 21, 2017 — Toshiba Medical will highlight its latest...
Siemens Healthineers to Showcase Magentom Vida MRI at RSNA 2017
Technology | Magnetic Resonance Imaging (MRI) | September 18, 2017
September 18, 2017 — Siemens Healthineers announced it will display the new Magnetom Vida 3T...
FDA Committee Votes to Expand Warning Labels on Gadolinium-Based Contrast Agents
News | Contrast Media | September 12, 2017
The U.S. Food and Drug Administration’s (FDA) Medical Imaging Drugs Advisory Committee (MIDAC) voted overwhelmingly...
News | Imaging | September 11, 2017
September 11, 2017 — Innovatus Imaging Corp., a newly created holding company formed by private equity firm Resilienc
Sponsored Content | Videos | Radiation Therapy | September 08, 2017
The new Visicoil MR is a helically-wound, flexible linear fiducial marker.
FDA Holds MIDAC Meeting on Gadolinium-Based Contrast Agents
News | Contrast Media | September 07, 2017
The U.S. Food and Drug Administration (FDA) announced it would hold a meeting of the Medical Imaging Drugs Advisory...
CIRS Launches New MRI Distortion Check Software
Technology | Magnetic Resonance Imaging (MRI) | September 06, 2017
MRI Distortion Check is a new, cloud-based solution designed to quickly and automatically quantify distortion in...
FDA Approves Guerbet's Dotarem for Pediatric Patients Younger Than Two Years
Technology | Magnetic Resonance Imaging (MRI) | September 06, 2017
September 6, 2017 — Guerbet LLC USA announced that the U.S.
Study Assesses Usefulness of MRI for Pediatric Sports-Related Concussion
News | Neuro Imaging | September 05, 2017
September 5, 2017 — A new study reviewed more than 5 years of records of...
The GE Healthcare Signa Premier MRI was among the top radiology stories from August 2017

The GE Healthcare Signa Premier MRI was among the top radiology stories from August 2017.

Feature | Imaging | September 01, 2017 | Melinda Taschetta-Millane
Here is the list of the most popular articles and videos on the Imaging Technology News (ITN) magazine website from the...
Overlay Init